Search Bar & Filters
Found 7 Actively Recruiting clinical trials
Actively Recruiting
Researchers are investigating the long-term effectiveness, safety, and tolerability of once-daily oral ASC30 compared to a placebo in adults with obesity or overweight and type 2 diabetes mellitus T2DM. This Phase III, global, randomized, double-blind, placebo-controlled study seeks to understand how different maintenance doses of ASC30 impact these participants over time. Participants will be randomly assigned to receive one of three doses of oral ASC30 tablets or matching placebo tablets once daily. The study compares these groups to evaluate the effects of ASC30 on weight and metabolic health over a 72-week period. Treatment is administered daily by mouth throughout the study. During participation, individuals will undergo regular assessments including measurements of body weight, blood sugar control HbA1c and fasting glucose, blood pressure, cholesterol, triglycerides, insulin levels, waist circumference, and body mass index. The main outcome is the percent change in body weight from the start to week 72. Safety and tolerability will be closely monitored, and the entire study duration spans about 72 weeks from baseline to final evaluation.
Actively Recruiting
Researchers are conducting a global Phase III clinical trial to evaluate the long-term effects of ASC30, an oral medication taken once daily, in adults with obesity or overweight who also have weight-related health conditions but do not have type 2 diabetes. The study aims to compare the efficacy, safety, and tolerability of three different maintenance doses of ASC30 against a placebo. This randomized, double-blind, placebo-controlled trial focuses on assessing body weight changes and related health measures over a lengthy period. Participants in this trial will be randomly assigned to one of four groups three groups receive different doses of ASC30 tablets daily, and one group receives matching placebo tablets daily. The treatment period is planned to last 72 weeks, during which participants will take their assigned oral tablets once a day. The study carefully monitors participants throughout the treatment phase to evaluate the effects of the medication compared to placebo. During the trial, participants will undergo regular assessments including measurements of body weight, waist circumference, blood pressure, blood glucose, cholesterol, insulin, and other metabolic markers from baseline through week 72. Researchers will also track safety and tolerability over this period. Participants can expect scheduled visits and evaluations to monitor changes in their health and response to the study medication over the roughly 1.5-year treatment duration.
Actively Recruiting
Researchers are evaluating the safety, tolerability, immune response, and pharmacodynamic effects of ACI-24.060 in people with prodromal Alzheimers disease and adults with Down syndrome who do not have dementia. This phase 1b2 study is divided into two parts Part 1 focuses on subjects with prodromal Alzheimers disease and includes subparts 1a and 1b, while Part 2 involves participants with Down syndrome. The study aims to better understand how ACI-24.060 affects these populations by comparing different doses and placebo over time. Participants receive various doses of ACI-24.060 or placebo at scheduled times over periods of 48 to 74 weeks depending on their group. In Part 1, those with prodromal Alzheimers disease are assigned to receive placebo or one of several doses of ACI-24.060, some with an additional adjuvant, over 48 to 74 weeks. Part 2 involves adults with Down syndrome who receive placebo or different doses of ACI-24.060 over 74 weeks, with options for dose adjustments based on prior testing in Part 1. The study is randomized and double-blinded to compare responses across groups. During the study, participants undergo safety monitoring including physical and neurological exams, MRI scans, and assessments of suicidal thoughts or behavior using the Columbia-Suicide Severity Rating Scale. Blood samples are taken to measure antibody levels against beta-amyloid. Researchers also evaluate cognitive and clinical measures relevant to Alzheimers disease and Down syndrome. The study lasts up to 100 weeks including screening and follow-up, with careful tracking of side effects and immune responses to understand the treatments effects over time.
Actively Recruiting
Seasonal influenza affects about one billion people worldwide each year, with 3 to 5 million cases being severe and causing up to 650,000 deaths annually. Vaccine effectiveness varies widely, often below 50%, and can be as low as 5% in people with weakened immune systems. This study aims to evaluate whether MK-1406 CD388 can help prevent influenza in adolescents and adults who are at increased risk of serious illness due to age, health conditions, or immune system weakness. Participants will receive a single dose of MK-1406 or a placebo through three subcutaneous injections during one study visit. The study is a Phase 3, randomized, double-blind, placebo-controlled trial conducted at multiple centers. It compares the safety, tolerability, and effectiveness of MK-1406 against placebo for preventing influenza in higher-risk individuals. During the study, participants will be monitored for up to approximately 24 weeks to track the occurrence of influenza-like illness, adverse events, and other health outcomes. Blood samples will be collected at specific times to measure drug levels and immune responses. Safety will be closely followed, including monitoring for injection site reactions and treatment-related antibodies. Participants health will be observed throughout the study period ending around 24 weeks post-dose.
Actively Recruiting
Researchers are studying patients with breast cancer who have limited nodal disease confirmed by biopsy and are undergoing primary surgery. The study evaluates targeted sentinel node biopsy TSNB as a method to assess axillary lymph node involvement and compares its outcomes to other staging methods. This observational audit aims to collect data on surgical results, arm lymphoedema, and disease progression, benchmarking against previous trials and current guidelines. Participants will undergo TSNB where the marked, biopsy-proven positive node is removed along with sentinel nodes, following standard local practices and protocols such as those used in the ATNEC trial. The marked node may be identified using clips, dyes, magnetic seeds, or other techniques. At least three nodes should be removed for adequate assessment. Further axillary treatment decisions after TSNB will be made by the treating multidisciplinary team based on local protocols. During the study, participants will be followed for up to 60 months with regular assessments of nodal metastases, identification rates of marked nodes, false negative rates, and arm lymphoedema. Secondary outcomes include axillary, regional, and local recurrence, disease-free survival, and overall survival. Data collection will include histology results and clinical follow-up to monitor outcomes and treatment effectiveness in this patient population.
Actively Recruiting
Healthy Volunteer
This clinical trial is designed to evaluate the Bridging Technique for treating nasolabial folds, commonly known as smile lines, in adults aged 30 to 65 years. The study aims to determine whether this new method, which uses very small amounts of hyaluronic acid HA dermal filler placed in thin horizontal threads under the folds, can safely improve their appearance and satisfy patients. The Bridging Technique was developed to provide natural-looking results with less product and reduced risk compared to traditional filler methods. Participants will receive a single treatment with AILEENE Vol. 2 HA dermal filler applied using the Bridging Technique to both nasolabial folds. The total filler used will not exceed 1.0 ml across both sides. An optional top-up treatment may be given at Week 2 or Week 4 if needed, using only the remaining filler allowance and a new sterile syringe. Follow-up visits include a virtual safety check at Week 2 and in-person evaluations at Week 4, Month 3, and Month 6. During the study, standardized photographs will be taken at baseline, Week 4, Month 3, and Month 6 to assess changes in fold severity, with independent reviewers unaware of the visit order. Participants will complete questionnaires about their satisfaction and experience. The primary outcome is the change in nasolabial fold severity, and secondary outcomes include overall aesthetic improvement. The study lasts six months, with no cost to participants and voluntary involvement.
Actively Recruiting
Researchers are conducting a multi-centre observational study to better understand giant cell arteritis GCA and polymyalgia rheumatica PMR, conditions mainly affecting people over 50 years old. The study aims to identify genetic factors that influence susceptibility to these diseases to provide new insights into how they develop. It includes both retrospective participants with confirmed diagnoses and prospective participants suspected of having these conditions, with some patients also enrolled in a registry monitoring tocilizumab treatment for relapsing or refractory GCA. The study collects detailed clinical, imaging, and molecular data, including genetic and proteomic analyses, from participants to characterize disease subtypes and impacts. Researchers also assess quality of life through patient-reported outcomes and track long-term prognosis by linking to health records. The study explores environmental factors and co-existing conditions to improve diagnosis, prognosis, and monitoring of disease activity, especially for patients receiving synthetic or biological disease-modifying anti-rheumatic drugs. Participants provide information during baseline assessments, including blood and urine samples for analysis, and complete questionnaires about their symptoms and quality of life. Follow-up occurs through health record review over an average of one year to evaluate diagnosis and disease outcomes. The primary measure is genetic susceptibility, with secondary outcomes focusing on disease characteristics, life impact, diagnosis, and disease activity. The study is sponsored by the University of Leeds and started in 2005, continuing through 2028.